Latest Conference Articles

April 18th 2016, 12:52pm

AACR Annual Meeting

Palbociclib may have antiproliferative effects when used as a neoadjuvant therapy for women with early stage breast cancer.

April 18th 2016, 11:20am

AACR Annual Meeting

A 70-gene signature (MammaPrint) demonstrated a high level of accuracy at identifying a large subset of women with clinically high-risk early stage breast cancer for whom adjuvant chemotherapy was unlikely to produce benefit.

April 18th 2016, 7:32am

AACR Annual Meeting

Michael Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the overall survival (OS) results of the CheckMate-069 study, which investigated the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) for the treatment of patients with melanoma.

April 18th 2016, 7:18am

AACR Annual Meeting

The combination of ipilimumab (Yervoy) and nivolumab (Opdivo) showed a 42% improvement in overall survival compared with ipilimumab monotherapy for patients with advanced melanoma in a 2-year assessment of the phase II CheckMate-069 trial.

April 18th 2016, 6:02am

AACR Annual Meeting

Yong-Chen William Lu, PhD, a fellow in the Surgery Branch of the National Cancer Institute, discusses a CD4 T-cell immunotherapy targeting MAGE-A3 that is showing early clinical responses in patients with metastatic cancer.

April 17th 2016, 1:18pm

AACR Annual Meeting

Rose K. Lai, MD, clinical associate professor of Neurology, University of Southern California, discusses results of the Glioma International Case Control study.

April 17th 2016, 1:07pm

AACR Annual Meeting

Treatment with the novel multikinase inhibitor entrectinib achieved objective responses in 79% of patients with solid tumors associated with NTRK, ROS-1, or ALK rearrangements.

April 17th 2016, 12:41pm

AACR Annual Meeting

A form of immunotherapy that harnesses the power of CD4 T-cells was shown to be safe and effective in patients with various types of metastatic cancers.

April 17th 2016, 11:56am

AACR Annual Meeting

F. Stephen Hodi, MD, director of the Melanoma Center at Dana-Farber Cancer Institute, discusses the results of the longest follow-up survival study of patients with advanced melanoma who were treated with single-agent nivolumab (Opdivo).

April 17th 2016, 8:50am

AACR Annual Meeting

Single-agent nivolumab demonstrated a robust 5-year overall survival rate of 34% for heavily pretreated patients with metastatic melanoma who had not received prior ipilimumab.

April 16th 2016, 12:06pm

European Lung Cancer Congress

Nicola Normanno, MD, chief of the Cell Biology and Biotherapy Unit, INT-Fondazione Pascale, Naples, Italy, discusses the benefit of plasma genotyping to predict response to EGFR-targeted therapy in patients with non-small cell lung cancer (NSCLC).

April 16th 2016, 12:04pm

European Lung Cancer Congress

Plasma-based genetic testing can effectively be used to determine whether a tissue biopsy is necessary for EGFR mutation analysis in patients with non–small cell lung cancer.

April 16th 2016, 11:57am

European Lung Cancer Congress

Raffaele Califano, MD, consultant in medical oncology at the Christie NHS Foundation Trust and University Hospital of South Manchester, discuses the potential for immunotherapy in small-cell lung cancer (SCLC).

April 16th 2016, 11:40am

European Lung Cancer Congress

Efficacy and safety remained strong 2 years following treatment with nivolumab for patients with advanced, refractory, squamous non-small–cell lung cancer, with an indication that cytokine levels could predict long-term outcomes.

April 16th 2016, 10:20am

European Lung Cancer Congress

Plasma genotyping can, in most cases, identify T790M-positivity in non-small cell lung cancer, which gives patients the option of receiving the targeted therapy osimertinib without the need for a tumor biopsy, according Geoffrey R. Oxnard, MD.

April 15th 2016, 12:45pm

Community Oncology Conference

Members of the Community Oncology Alliance have issued a call to arms to spur a greater lobbying effort to stop a plan by The Centers for Medicare & Medicare Centers to implement a drug reimbursement change under Medicare Part B.

April 15th 2016, 12:29pm

European Lung Cancer Congress

The first analysis of a trial investigating durvalumab in combination with gefitinib (Iressa) showed encouraging anti-tumor activity and tolerability in patients with non–small cell lung cancer and EGFR mutations that were tyrosine-kinase inhibitor-naïve.

April 15th 2016, 12:12pm

European Lung Cancer Congress

Luis Paz-Ares, MD, PhD, Professor of Medicine at Hospital Universitario 12 de Octubre in Madrid, Spain, discusses a subgroup analysis of patients with EGFR-expressing tumors from the SQUIRE trial, a phase III study of gemcitabine–cisplatin plus necitumumab versus gemcitabine–cisplatin alone as first-line treatment for patients with stage IV squamous non-small cell lung cancer (NSCLC).

April 15th 2016, 10:31am

European Lung Cancer Congress

Suresh Ramalingam, MD, professor of Hematology and Medical Oncology at Emory School of Medicine and deputy director of Winship Cancer Institute, discusses first-line treatment with single-agent osimertinib in patients with EGFR-mutated non–small cell lung cancer (NSCLC).

April 15th 2016, 8:18am

European Lung Cancer Congress

Adding necitumumab to conventional chemotherapy improved outcomes in patients with metastatic squamous non–small cell lung cancer in the phase III SQUIRE trial, but the greatest benefit was derived by patients with EGFR-expressing tumors.